News | EP Mapping and Imaging Systems | July 07, 2016

Abbott Announces Positive Clinical Results with FIRM-Guided Rotor Ablation for Atrial Fibrillation

Trio of studies presented at Cardiostim conference support technique that allows more individualized treatment of cardiac arrhythmias

Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016

July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits associated with focal impulse rotor modulation (FIRM)-guided rotor ablation for atrial fibrillation. The investigator-sponsored studies, which evaluated the use of Abbott’s RhythmView technology, were presented at the Cardiostim-EHRA Europace 2016 conference, June 8-11 in Nice, France.

FIRM-guided therapy enables physicians to identify and locate rotors – unique patient-specific sources that sustain serious heart rhythm disorders, including atrial fibrillation. With the ability to visualize individual rotors, physicians can tailor treatment approaches for each patient.

“The latest data presented at Cardiostim adds to a growing body of clinical evidence in support of the FIRM-guided approach in combination with conventional ablation, with the goals of optimizing treatment planning for atrial fibrillation and improving long-term results for our patients,” said Prof. Stefan Spitzer of the Praxisklinik Herz und Gefäße in Dresden, Germany, who authored one of the data presentations at the conference. “I look forward to additional analyses that further investigate this important therapy option.”

The studies presented at Cardiostim investigated the benefits associated with FIRM-guided rotor ablation when combined with the traditional procedure for atrial fibrillation. Key findings include:

  • Spitzer presented results from 58 patients finding 80.8 percent of patients free from atrial fibrillation at 12 months post-treatment with FIRM-guided ablation for redo cases of persistent atrial fibrillation, with 83 percent of patients having long-standing persistent atrial fibrillation;
  • Tamas Szili-Torok, M.D., Rotterdam, Netherlands, presented the first results from the European-Focal Impulse and Rotor Modulation Registry (E-FIRM) of 138 patients showing 78 percent and 72 percent of patients in sinus rhythm following treatment with the FIRM-guided ablation at six and 12 months, respectively; and
  • Haroon Rashid, M.D., Falls Church, Va., shared data examining the relationship between stable rotors and obstructive sleep apnea in 47 patients, showing 78.6 percent of patients in sinus rhythm after FIRM-guided ablation, despite the presence of obstructive sleep apnea.

During a FIRM-guided rotor ablation procedure for atrial fibrillation, physicians use Abbott’s proprietary technology to identify and visualize rotors, important sustaining mechanisms of cardiac arrhythmias. Because arrhythmias develop as a result of both electrical and anatomic abnormalities, every patient needs to be individually diagnosed and treated. The system offers a patient-specific solution that enables physicians, for the very first time, to identify and ablate the unique sources that sustain serious heart rhythm disorders.

Read about first reports on the FIRM rotor mapping technique at HRS.

 

For more information: www.abbott.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init